MX2014004469A - Metodos y composiciones para tratar inflamacion y lesion isquemica. - Google Patents
Metodos y composiciones para tratar inflamacion y lesion isquemica.Info
- Publication number
- MX2014004469A MX2014004469A MX2014004469A MX2014004469A MX2014004469A MX 2014004469 A MX2014004469 A MX 2014004469A MX 2014004469 A MX2014004469 A MX 2014004469A MX 2014004469 A MX2014004469 A MX 2014004469A MX 2014004469 A MX2014004469 A MX 2014004469A
- Authority
- MX
- Mexico
- Prior art keywords
- cystamine
- cysteamine
- derivative
- ischemic injury
- treating ischemic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563034P | 2011-11-22 | 2011-11-22 | |
| PCT/US2012/066288 WO2013078335A1 (en) | 2011-11-22 | 2012-11-21 | Cysteamine and/or cystamine for treating ischemic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014004469A true MX2014004469A (es) | 2014-08-01 |
Family
ID=47297472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004469A MX2014004469A (es) | 2011-11-22 | 2012-11-21 | Metodos y composiciones para tratar inflamacion y lesion isquemica. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140322315A1 (enExample) |
| EP (1) | EP2782564B1 (enExample) |
| JP (1) | JP6411215B2 (enExample) |
| KR (1) | KR20140097132A (enExample) |
| CN (2) | CN108042517A (enExample) |
| AU (1) | AU2012340670B2 (enExample) |
| BR (1) | BR112014012167A2 (enExample) |
| CA (1) | CA2851387A1 (enExample) |
| HK (1) | HK1202440A1 (enExample) |
| IL (1) | IL232608A0 (enExample) |
| MX (1) | MX2014004469A (enExample) |
| MY (1) | MY165953A (enExample) |
| RU (1) | RU2638807C2 (enExample) |
| SG (2) | SG11201402472QA (enExample) |
| WO (1) | WO2013078335A1 (enExample) |
| ZA (1) | ZA201402290B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI649100B (zh) * | 2013-06-17 | 2019-02-01 | 地平線罕見醫學製藥有限責任公司 | 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法 |
| ES2770113T3 (es) * | 2015-07-02 | 2020-06-30 | Horizon Orphan Llc | Análogos de la cisteamina resistentes a la ADO y sus usos |
| CN106591461A (zh) * | 2016-12-29 | 2017-04-26 | 天津协和华美医学诊断技术有限公司 | 一种检测遗传性易栓症相关基因群的检测试剂盒 |
| CN110392568A (zh) * | 2017-01-19 | 2019-10-29 | 耳科制药公司 | N-乙酰半胱氨酸的制剂及其用途 |
| EP3573994A4 (en) | 2017-01-25 | 2020-11-11 | Adare Pharmaceuticals, Inc. | MEDICINES OF CYSTEAMINE |
| WO2021022012A1 (en) * | 2019-07-30 | 2021-02-04 | The Regents Of The University Of California | Methods and composition for treating respiratory obstructive diseases |
| CN113484453B (zh) * | 2021-07-07 | 2022-08-09 | 天津中医药大学 | 一种缺血性脑卒中预警方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4301146A (en) | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
| FR2549051B1 (fr) | 1983-06-22 | 1986-05-16 | Centre Nat Rech Scient | Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation |
| FR2573077B1 (fr) * | 1984-11-13 | 1987-02-13 | Sanofi Sa | Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| EP0306937A3 (en) * | 1987-09-08 | 1990-07-25 | The Green Cross Corporation | Platelet agglutination-inhibiting agent |
| JPH02243619A (ja) * | 1989-03-15 | 1990-09-27 | Green Cross Corp:The | 抗血小板凝集剤 |
| WO1990014087A1 (en) | 1989-05-17 | 1990-11-29 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as antiischemic agents |
| US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| US5436255A (en) | 1992-07-23 | 1995-07-25 | Pfizer Inc. | Method of treating diseases susceptable to treatment by blocking NMDA-receptors |
| TW281670B (enExample) | 1993-09-02 | 1996-07-21 | Hoffmann La Roche | |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610736B (en) | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| WO1997023202A1 (en) | 1995-12-22 | 1997-07-03 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON | Subtype-selective nmda receptor ligands and the use thereof |
| US6087398A (en) * | 1996-03-01 | 2000-07-11 | South Alabama Medical Science Foundation | Sickle cell anemia treatment |
| FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
| DE19643790A1 (de) | 1996-10-30 | 1998-05-07 | Merck Patent Gmbh | Benzoxazol-Derivat |
| PL340080A1 (en) | 1997-10-24 | 2001-01-15 | Warner Lambert Co | Method of treating disease-related or post-drug dyskinesias |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| WO2000025109A1 (en) | 1998-10-28 | 2000-05-04 | Scofield Dillon F | Electrodynamic particle size analyzer |
| US6291499B1 (en) | 1999-10-29 | 2001-09-18 | Merck & Co., Inc. | 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
| US6432976B1 (en) | 1999-10-29 | 2002-08-13 | Merck & Co., Inc. | 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists |
| CA2386441A1 (en) | 1999-10-29 | 2001-05-03 | Merck Sharp & Dohme Limited | Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| US6316474B1 (en) | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
| US6369076B1 (en) | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| US6489477B1 (en) | 1999-10-29 | 2002-12-03 | Merck & Co., Inc. | 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists |
| RU2367423C2 (ru) * | 2003-12-19 | 2009-09-20 | ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД | Композиции и способы для лечения диабета |
| RU2387445C2 (ru) * | 2004-05-03 | 2010-04-27 | ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД | Материалы и способы модуляции метаболизма |
| JP5583022B2 (ja) * | 2007-11-30 | 2014-09-03 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法 |
| RU2428192C1 (ru) * | 2010-06-10 | 2011-09-10 | Войсковая Часть 41598 | Радиозащитное средство |
-
2012
- 2012-11-21 MX MX2014004469A patent/MX2014004469A/es unknown
- 2012-11-21 BR BR112014012167A patent/BR112014012167A2/pt not_active IP Right Cessation
- 2012-11-21 SG SG11201402472QA patent/SG11201402472QA/en unknown
- 2012-11-21 CA CA2851387A patent/CA2851387A1/en not_active Abandoned
- 2012-11-21 RU RU2014125282A patent/RU2638807C2/ru not_active IP Right Cessation
- 2012-11-21 CN CN201810067673.7A patent/CN108042517A/zh active Pending
- 2012-11-21 EP EP12798116.5A patent/EP2782564B1/en not_active Not-in-force
- 2012-11-21 CN CN201280057439.7A patent/CN103974698A/zh active Pending
- 2012-11-21 WO PCT/US2012/066288 patent/WO2013078335A1/en not_active Ceased
- 2012-11-21 KR KR1020147010492A patent/KR20140097132A/ko not_active Ceased
- 2012-11-21 AU AU2012340670A patent/AU2012340670B2/en not_active Ceased
- 2012-11-21 MY MYPI2014001446A patent/MY165953A/en unknown
- 2012-11-21 US US14/360,095 patent/US20140322315A1/en not_active Abandoned
- 2012-11-21 HK HK15103104.0A patent/HK1202440A1/xx unknown
- 2012-11-21 SG SG10201800159QA patent/SG10201800159QA/en unknown
- 2012-11-21 JP JP2014542590A patent/JP6411215B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-27 ZA ZA2014/02290A patent/ZA201402290B/en unknown
- 2014-05-14 IL IL232608A patent/IL232608A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012340670A1 (en) | 2014-04-17 |
| SG10201800159QA (en) | 2018-02-27 |
| RU2638807C2 (ru) | 2017-12-15 |
| CA2851387A1 (en) | 2013-05-30 |
| EP2782564A1 (en) | 2014-10-01 |
| BR112014012167A2 (pt) | 2017-05-30 |
| SG11201402472QA (en) | 2014-06-27 |
| WO2013078335A1 (en) | 2013-05-30 |
| JP6411215B2 (ja) | 2018-10-24 |
| AU2012340670B2 (en) | 2016-12-22 |
| KR20140097132A (ko) | 2014-08-06 |
| MY165953A (en) | 2018-05-18 |
| ZA201402290B (en) | 2017-06-28 |
| JP2014533701A (ja) | 2014-12-15 |
| US20140322315A1 (en) | 2014-10-30 |
| CN103974698A (zh) | 2014-08-06 |
| EP2782564B1 (en) | 2019-01-09 |
| IL232608A0 (en) | 2014-06-30 |
| RU2014125282A (ru) | 2015-12-27 |
| HK1202440A1 (zh) | 2015-10-02 |
| CN108042517A (zh) | 2018-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014035140A3 (en) | Compounds and compositions for modulating histone methyltransferase activity | |
| MX2014004469A (es) | Metodos y composiciones para tratar inflamacion y lesion isquemica. | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| PH12014500767A1 (en) | Compositions for the treatment of dry eye | |
| CR20150216A (es) | Composiciones y métodos para tratar proteinopatías | |
| ECSP10010007A (es) | Tratamiento con ligandos alpha-7-selectivos | |
| MX2021008281A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
| ZA201600453B (en) | Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders | |
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| CO2017003011A2 (es) | Derivados de benzodiazepina citotóxicos | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| TN2010000096A1 (en) | Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors | |
| SI3220916T1 (sl) | Postopek zdravljenja raka z n-((4,6-dimetil-2-okso-1,2-dihidropiridin-3 -il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'- (morfolinometil)-(1,1'-bifenil)-3-karboksamidom | |
| PH12015502659A1 (en) | Surface treatment compositions comprising photochromic dyes | |
| EP3054954A4 (en) | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma | |
| CR20150047A (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| MX2015017253A (es) | Composiciones y metodos para tratar trastornos metabolicos. | |
| MX389020B (es) | Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. | |
| WO2015017529A3 (en) | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules | |
| BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
| WO2012061536A3 (en) | Methods for treating hair loss disorders | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| CL2014002485A1 (es) | Composición que comprende lactoferrina para prevenir, mejorar o tratar la diarrea. | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |